JNJ's Not Pulling The Plug On "Imetelstat" Sends Geron Corp. Shares UP 23% Mid-Morning

Johnson & Johnson's review of data from two studies of the Geron Corp drug imetelstat has concluded that it warrants continued work and that it is still reserving the right to quit if the data don’t hold up later in the year.